The Editors of AHFS Drug Information® (AHFS DI®) wish to inform you of an error in the alpelisib monograph 10:00.
In the AHFS monograph, the error appears under the subhead Breast Cancer, in Dosage and Administration: Dosage. (This is in the second column on page 870 of the printed edition of AHFS DI 2022®.) In the first sentence under this subhead, the statement should read:
“For use in combination with fulvestrant in the treatment of hormone receptor-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer in men and postmenopausal women with disease progression following endocrine therapy, the recommended adult dosage of alpelisib is 300 mg (two 150-mg tablets) once daily.”
In the AHFS Essentials monograph, this statement should read:
“Oral: 300 mg (two 150-mg tablets) once daily; use in combination with fulvestrant 500 mg by IM injection on days 1, 15, and 29 and then once monthly thereafter.”
